Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma

Table 3

Hematologic and nonhematologic toxicities during bortezomib retreatment therapy according to the NCI-CTCAE 4.0.

Grade	Number of patients in total 30, (%)
	1	2	3	4
Leukopenia	5 (17)	9 (30)	8 (27)	3 (10)
Neutropenia	3 (10)	8 (27)	9 (30)	5 (17)
Anemia	8 (27)	15 (50)	3 (10)	0
Thrombocytopenia	5 (17)	10 (33)	7 (23)	6 (20)
Creatinine	2 (7)	3 (10)	1 (3)	0
Anorexia	8 (27)	0	0	0
Nausea	6 (20)	1 (3)	0	0
Vomiting	1 (3)	1 (3)	0	0
Diarrhea	2 (7)	3 (10)	0	0
Constipation	5 (17)	3 (10)	0	0
Dyspnea	3 (10)	1 (3)	0	0
Pneumonia	0	0	5 (17)	0
Fever/bacteremia	0	0	3 (10)	0
Sensory neuropathy	10 (33)	8 (27)	1 (3)	0
Motor neuropathy	4 (13)	1 (3)	1 (3)	0
Pain	10 (33)	4 (13)	0	0
Dizziness	11 (37)	0	0	0
Delirium	1 (3)	0	0	0
Insomnia/somnolence	6 (20)	0	0	0
Asthenia	9 (30)	11 (37)	1 (3)	0
Rash	2 (7)	0	0	0

NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.